Roth Capital started coverage on shares of Intec Pharma (NASDAQ:NTEC) in a research report sent to investors on Friday, The Fly reports. The firm issued a buy rating and a $8.50 price target on the biotechnology company’s stock.
Other equities research analysts also recently issued reports about the stock. Zacks Investment Research downgraded shares of Intec Pharma from a hold rating to a sell rating in a research note on Wednesday, July 25th. Oppenheimer set a $15.00 price objective on shares of Intec Pharma and gave the stock a buy rating in a research note on Wednesday, August 15th. Finally, HC Wainwright set a $16.00 price objective on shares of Intec Pharma and gave the stock a buy rating in a research note on Thursday, August 16th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of Buy and an average price target of $11.40.
Shares of NTEC opened at $4.83 on Friday. The company has a market capitalization of $185.47 million, a price-to-earnings ratio of -2.92 and a beta of 0.98. Intec Pharma has a twelve month low of $3.55 and a twelve month high of $9.00.
Intec Pharma (NASDAQ:NTEC) last announced its earnings results on Wednesday, August 15th. The biotechnology company reported ($0.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.32) by ($0.02). Equities research analysts anticipate that Intec Pharma will post -1.36 EPS for the current year.
Several large investors have recently bought and sold shares of the company. 683 Capital Management LLC acquired a new stake in shares of Intec Pharma during the second quarter worth $660,000. Acuta Capital Partners LLC lifted its stake in shares of Intec Pharma by 8.7% during the second quarter. Acuta Capital Partners LLC now owns 2,962,568 shares of the biotechnology company’s stock worth $13,035,000 after buying an additional 238,285 shares during the period. Prosight Management LP acquired a new stake in shares of Intec Pharma during the second quarter worth $4,951,000. Renaissance Technologies LLC lifted its stake in shares of Intec Pharma by 484.3% during the second quarter. Renaissance Technologies LLC now owns 88,898 shares of the biotechnology company’s stock worth $391,000 after buying an additional 73,684 shares during the period. Finally, DAFNA Capital Management LLC acquired a new stake in shares of Intec Pharma during the second quarter worth $2,502,000. Institutional investors and hedge funds own 45.09% of the company’s stock.
About Intec Pharma
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.
Featured Article: Intrinsic Value
Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.